FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897905042> ?p ?o ?g. }

• W2897905042 abstract "Retinoblastoma (RB) is a well‑vascularized tumor dependent on angiogenesis. The present study aimed to explore whether microRNA (miR)‑182 regulates cell viability, invasion and angiogenesis in RB via the phosphatidylinositol‑3‑OH kinase (PI3K)/protein kinase B (AKT) signaling pathway and by targeting cell adhesion molecule 2 (CADM2). The expression levels of miR‑182 and CADM2 were initially detected in RB tissues from patients with RB who underwent ophthalmectomy, and normal retinal tissues collected from other trauma patients who underwent eye enucleation. To determine whether CADM2 was targeted by miR‑182, a dual luciferase reporter assay was conducted. Subsequently, Y79 and WERI‑Rb‑1 RB cells were transfected with a miR‑182 mimic or miR‑182 inhibitor, or small interfering RNA against CADM2, in order to investigate the effects of miR‑182 on viability and invasion, which were detected using MTT and Transwell assays, respectively. In addition, to determine whether the regulatory mechanism underlying the effects of miR‑182 was associated with the PI3K/AKT signaling pathway, the expression levels of associated genes were detected by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. A xenograft tumor model in nude mice was also established, in order to evaluate the effects of miR‑182 on tumor growth and angiogenesis. The results indicated that miR‑182 expression was increased and CADM2 expression was reduced in RB tissues; CADM2 was confirmed to be targeted and negatively regulated by miR‑182. When the expression of miR‑182 was downregulated, cell viability, invasion, tumor volume and angiogenesis were significantly decreased. Furthermore, the expression levels of PI3K/AKT signaling pathway‑associated genes were increased in response to miR‑182 overexpression or CADM2 silencing. Taken together, these results suggested that inhibition of miR‑182 may suppress cell viability, invasion and angiogenesis in RB through inactivation of the PI3K/AKT pathway and CADM2 upregulation. This mechanism may reveal a novel potential therapeutic target." @default.
• W2897905042 created "2018-10-26" @default.
• W2897905042 creator A5003331841 @default.
• W2897905042 creator A5013900921 @default.
• W2897905042 creator A5016761859 @default.
• W2897905042 creator A5042100539 @default.
• W2897905042 creator A5080335185 @default.
• W2897905042 creator A5086405286 @default.
• W2897905042 date "2018-10-09" @default.
• W2897905042 modified "2023-09-27" @default.
• W2897905042 title "Downregulation of microRNA‑182 inhibits cell viability, invasion and angiogenesis in retinoblastoma through inhibition of the PI3K/AKT pathway and CADM2 upregulation" @default.
• W2897905042 cites W1600744146 @default.
• W2897905042 cites W1731637226 @default.
• W2897905042 cites W1847228221 @default.
• W2897905042 cites W1966668576 @default.
• W2897905042 cites W1979210337 @default.
• W2897905042 cites W1994793678 @default.
• W2897905042 cites W2004018125 @default.
• W2897905042 cites W2005846307 @default.
• W2897905042 cites W2006034168 @default.
• W2897905042 cites W2030950050 @default.
• W2897905042 cites W2032627358 @default.
• W2897905042 cites W2034561173 @default.
• W2897905042 cites W2037950862 @default.
• W2897905042 cites W2044505245 @default.
• W2897905042 cites W2046746208 @default.
• W2897905042 cites W2048756258 @default.
• W2897905042 cites W2060026948 @default.
• W2897905042 cites W2074341094 @default.
• W2897905042 cites W2080395975 @default.
• W2897905042 cites W2084263257 @default.
• W2897905042 cites W2101741807 @default.
• W2897905042 cites W2107277218 @default.
• W2897905042 cites W2107890714 @default.
• W2897905042 cites W2114175644 @default.
• W2897905042 cites W2125672675 @default.
• W2897905042 cites W2126940189 @default.
• W2897905042 cites W2137429301 @default.
• W2897905042 cites W2146236251 @default.
• W2897905042 cites W2165708858 @default.
• W2897905042 cites W2297201174 @default.
• W2897905042 cites W2405264636 @default.
• W2897905042 cites W2413133207 @default.
• W2897905042 cites W2424555050 @default.
• W2897905042 cites W2509821482 @default.
• W2897905042 cites W2580759733 @default.
• W2897905042 cites W2742078830 @default.
• W2897905042 cites W2763981440 @default.
• W2897905042 cites W2767954213 @default.
• W2897905042 doi "https://doi.org/10.3892/ijo.2018.4587" @default.
• W2897905042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30320366" @default.
• W2897905042 hasPublicationYear "2018" @default.
• W2897905042 type Work @default.
• W2897905042 sameAs 2897905042 @default.
• W2897905042 citedByCount "11" @default.
• W2897905042 countsByYear W28979050422019 @default.
• W2897905042 countsByYear W28979050422021 @default.
• W2897905042 countsByYear W28979050422022 @default.
• W2897905042 countsByYear W28979050422023 @default.
• W2897905042 crossrefType "journal-article" @default.
• W2897905042 hasAuthorship W2897905042A5003331841 @default.
• W2897905042 hasAuthorship W2897905042A5013900921 @default.
• W2897905042 hasAuthorship W2897905042A5016761859 @default.
• W2897905042 hasAuthorship W2897905042A5042100539 @default.
• W2897905042 hasAuthorship W2897905042A5080335185 @default.
• W2897905042 hasAuthorship W2897905042A5086405286 @default.
• W2897905042 hasBestOaLocation W28979050421 @default.
• W2897905042 hasConcept C104317684 @default.
• W2897905042 hasConcept C127561419 @default.
• W2897905042 hasConcept C145059251 @default.
• W2897905042 hasConcept C1491633281 @default.
• W2897905042 hasConcept C153911025 @default.
• W2897905042 hasConcept C2780394083 @default.
• W2897905042 hasConcept C29537977 @default.
• W2897905042 hasConcept C502942594 @default.
• W2897905042 hasConcept C53227056 @default.
• W2897905042 hasConcept C55493867 @default.
• W2897905042 hasConcept C62478195 @default.
• W2897905042 hasConcept C75217442 @default.
• W2897905042 hasConcept C86554907 @default.
• W2897905042 hasConcept C86803240 @default.
• W2897905042 hasConcept C95444343 @default.
• W2897905042 hasConceptScore W2897905042C104317684 @default.
• W2897905042 hasConceptScore W2897905042C127561419 @default.
• W2897905042 hasConceptScore W2897905042C145059251 @default.
• W2897905042 hasConceptScore W2897905042C1491633281 @default.
• W2897905042 hasConceptScore W2897905042C153911025 @default.
• W2897905042 hasConceptScore W2897905042C2780394083 @default.
• W2897905042 hasConceptScore W2897905042C29537977 @default.
• W2897905042 hasConceptScore W2897905042C502942594 @default.
• W2897905042 hasConceptScore W2897905042C53227056 @default.
• W2897905042 hasConceptScore W2897905042C55493867 @default.
• W2897905042 hasConceptScore W2897905042C62478195 @default.
• W2897905042 hasConceptScore W2897905042C75217442 @default.
• W2897905042 hasConceptScore W2897905042C86554907 @default.
• W2897905042 hasConceptScore W2897905042C86803240 @default.
• W2897905042 hasConceptScore W2897905042C95444343 @default.
• W2897905042 hasLocation W28979050421 @default.
• W2897905042 hasLocation W28979050422 @default.
• W2897905042 hasOpenAccess W2897905042 @default.

• next